[go: up one dir, main page]

EA201001814A1 - Лечение митохондриальных заболеваний миметиками эритропоэтина - Google Patents

Лечение митохондриальных заболеваний миметиками эритропоэтина

Info

Publication number
EA201001814A1
EA201001814A1 EA201001814A EA201001814A EA201001814A1 EA 201001814 A1 EA201001814 A1 EA 201001814A1 EA 201001814 A EA201001814 A EA 201001814A EA 201001814 A EA201001814 A EA 201001814A EA 201001814 A1 EA201001814 A1 EA 201001814A1
Authority
EA
Eurasian Patent Office
Prior art keywords
memetics
erythropoietin
treatment
disorders
mitochondrial diseases
Prior art date
Application number
EA201001814A
Other languages
English (en)
Inventor
Гай М. Миллер
Уильям Д. Шрэдер
Виктория Кейфетс
Original Assignee
Эдисон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эдисон Фармасьютикалз, Инк. filed Critical Эдисон Фармасьютикалз, Инк.
Publication of EA201001814A1 publication Critical patent/EA201001814A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Раскрываются способы лечения митохондриальных нарушений, не являющихся нарушениями дыхательной цепи, с применением композиций, содержащих ЭПО-миметические соединения или соединения, способные повысить уровни эндогенного ЭПО или стимулировать эритропоэз. Также раскрываются способы лечения атаксии Фридрейха, синдрома Лея или других нарушений путем повышения экспрессии фратаксина ЭПО-миметическим соединением или соединением, способным повысить уровни эндогенного ЭПО или стимулировать эритропоэз.
EA201001814A 2008-05-22 2009-05-20 Лечение митохондриальных заболеваний миметиками эритропоэтина EA201001814A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12862608P 2008-05-22 2008-05-22
PCT/US2009/044709 WO2009143268A2 (en) 2008-05-22 2009-05-20 Treatment of mitochondrial diseases with an erythropoietin mimetic

Publications (1)

Publication Number Publication Date
EA201001814A1 true EA201001814A1 (ru) 2011-04-29

Family

ID=41213457

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001814A EA201001814A1 (ru) 2008-05-22 2009-05-20 Лечение митохондриальных заболеваний миметиками эритропоэтина

Country Status (6)

Country Link
US (1) US20090291092A1 (ru)
EP (1) EP2303309A2 (ru)
CA (1) CA2724841A1 (ru)
EA (1) EA201001814A1 (ru)
MX (1) MX2010012486A (ru)
WO (1) WO2009143268A2 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470798B2 (en) 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
HUE033304T2 (en) * 2005-06-01 2017-11-28 Bioelectron Tech Corp Redoxactive therapeutic agents for the treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
US20120129188A1 (en) * 2006-07-20 2012-05-24 Rosalind Franklin University Of Medicine And Science Circulating cytochrome c as biomarker of reperfusion injury and responsiveness to mitochondrial targeted interventions
CA2674368A1 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EP2237664A4 (en) * 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
JP5798481B2 (ja) 2008-06-25 2015-10-21 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体
BRPI0918139B1 (pt) 2008-09-10 2024-04-30 Ptc Therapeutics, Inc Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
WO2010045220A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
HUE041714T2 (hu) 2008-10-28 2019-05-28 Bioelectron Tech Corp Kompozíció, amely tartalmaz alfa tokotrienolkinont és annak intermediereit
WO2010126911A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
EA028677B1 (ru) * 2009-08-26 2017-12-29 Биоэлектрон Текнолоджи Корпорейшн Способ лечения, предотвращения и/или улучшения нейронального повреждения, связанного с ишемией головного мозга
EP2734512B1 (en) 2011-07-19 2019-11-20 Bioelectron Technology Corporation Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
CN102895655B (zh) * 2012-09-28 2014-04-02 上海交通大学医学院附属新华医院 促红细胞生成素微球在制备治帕金森病药物中的应用
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
WO2015026708A2 (en) * 2013-08-20 2015-02-26 Wilson Robert B Amelioration of the effects of friedriech's ataxia
HK1224204A1 (en) * 2013-10-29 2017-08-18 Tokyo University Of Agriculture Frataxin enhancer
RU2770091C2 (ru) 2014-12-16 2022-04-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида
WO2017027810A2 (en) 2015-08-12 2017-02-16 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
WO2017106786A1 (en) 2015-12-16 2017-06-22 Bioelectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
AU2016369616B2 (en) 2015-12-17 2021-03-25 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
CN109394763A (zh) * 2017-08-18 2019-03-01 上海市第人民医院 HIF-1α小分子激活剂在制备用于治疗神经退行性疾病的药物中的应用
WO2019083995A1 (en) * 2017-10-23 2019-05-02 Cell Medicine, Inc. MESENCHYMAL STEM CELL THERAPY OF LEIGH SYNDROME
WO2019148471A1 (zh) * 2018-02-02 2019-08-08 中国人民解放军军事科学院军事医学研究院 Fg-4592或其盐的新用途以及药品和保健品
HUE066196T2 (hu) 2018-10-17 2024-07-28 Ptc Therapeutics Inc 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére
CA3225266A1 (en) 2021-07-08 2023-01-12 Swathi PINNAMANENI Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US7410941B1 (en) * 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
CA2437333A1 (en) * 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
EP1463823B1 (en) * 2001-12-06 2013-03-06 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
AU2003218045A1 (en) * 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
AU2003256336A1 (en) * 2002-06-28 2004-01-19 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
US20040009908A1 (en) * 2002-07-10 2004-01-15 Stamler Jonathan S. Methods for treating or preventing ischemic injury
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
WO2005084364A2 (en) * 2004-03-03 2005-09-15 The Kenneth S. Warren Institue, Inc. Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
AT500929B1 (de) * 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
CA2674368A1 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity

Also Published As

Publication number Publication date
EP2303309A2 (en) 2011-04-06
WO2009143268A3 (en) 2010-01-14
CA2724841A1 (en) 2009-11-26
WO2009143268A2 (en) 2009-11-26
MX2010012486A (es) 2010-12-02
US20090291092A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
EA201001814A1 (ru) Лечение митохондриальных заболеваний миметиками эритропоэтина
MX2022005399A (es) Compuestos.
EA201001639A1 (ru) Композиции и способы их получения и применения
GT200700039A (es) Derivados de triazolopirazina
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
ECSP11010885A (es) Heteroarilos sustituidos
CY1111166T1 (el) Νεα παραγωγα 1,4-βενζοθειεπινο-1,1-διοξειδιου υποκατεστημενα με ριζες βενζυλιου, μεθοδοι διεργασιων για την παρασκευη τους, φαρμακα που περιεχουν αυτες τις ενωσεις και η χρηση τους
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
CY1114091T1 (el) ΠΑΡΑΓΟΝΤΕΣ ΓΙΑ ΠΡΟΛΗΨΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΔΙΑΤΑΡΑΧΩΝ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΟΥΝ ΔΙΑΦΟΡΟΠΟΙΗΣΗ ΤΩΝ ΥΠΟΔΟΧΕΩΝ RyR
SMT201300096B (it) Inibitori di prolil idrossilasi
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
MA32505B1 (fr) 5-alcynyl-pyrimidines
MX390067B (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas.
CO6341529A2 (es) Composicion fungicida y metodo para el control de las enfermedades de las plantas
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
EA201270778A1 (ru) Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
MX380421B (es) Compuestos herbicidas de pirimidiniloxi benceno sustituido.
SV2011003944A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexano de ccr2
EA201070250A1 (ru) Противомикробный парентеральный состав
CY1117706T1 (el) Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac